<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40277">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02025023</url>
  </required_header>
  <id_info>
    <org_study_id>42336-D</org_study_id>
    <nct_id>NCT02025023</nct_id>
  </id_info>
  <brief_title>Chalazia Treatment Study</brief_title>
  <acronym>CTS</acronym>
  <official_title>Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Local injection of 5-fluorouracil into a chalazion (stye) is as effective as local injection
      of triamcinolone (steroid) and incision and curettage for treatment of chalazia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective randomized interventional study comparing four current
      standard-of-care treatments for chalazia:  incision and curettage, local injection of
      triamcinolone, local injection of 5-FU, and local injection of combination
      triamcinolone/5-FU.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Size of chalazion</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chalazion</condition>
  <arm_group>
    <arm_group_label>Incision and Curettage</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A  vertical incision over the area of  chalazion will be done. Inflammatory material will be removed  and the chalazion capsule will be excised.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Injection of Triamcinolone Acetonide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.1 ml of triamcinolone is injected directly in the chalazion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Injection of 5-fluorouracil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.1 ml of 5-fluorouracil is injected directly in the lesion transconjunctivally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Injection of triamcinolone/5FU mixture</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.1 ml of a 4:1 mixture of 4 parts 5-FU and 1 part triamcinolone is injected in the lesion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil Injection</intervention_name>
    <description>If the chalazion is present at follow-up visit, another injection of 5-FU will be given.</description>
    <arm_group_label>Injection of 5-fluorouracil</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Acetonide</intervention_name>
    <description>If chalazion present at follow-up, another Triamcinolone injection will be done.</description>
    <arm_group_label>Injection of Triamcinolone Acetonide</arm_group_label>
    <other_name>triamcinolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Incision and Curettage</intervention_name>
    <description>If chalazion present at follow-up visit, patient will be randomized to receive local injection of either triamcinolone, 5-FU, or triamcinolone/5-FU mixture.</description>
    <arm_group_label>Incision and Curettage</arm_group_label>
    <arm_group_label>Injection of Triamcinolone Acetonide</arm_group_label>
    <arm_group_label>Injection of 5-fluorouracil</arm_group_label>
    <arm_group_label>Injection of triamcinolone/5FU mixture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Acetonide/5-fluorouracil mixture</intervention_name>
    <description>If chalazion persists at follow-up visit, another injection of triamcinolone/5-FU mixture will be done.</description>
    <arm_group_label>Injection of triamcinolone/5FU mixture</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Single or multiple chalazia in a single eyelid

        Exclusion Criteria:

          -  Chalazia present for less than one month and no previous injection or incision and
             curettage
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shu-Hong Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington Eye Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shu-Hong Chang, MD</last_name>
    <phone>206-744-2020</phone>
    <email>shuchang@uw.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sue Rath, COT</last_name>
    <phone>206-897-4331</phone>
    <email>raths@uw.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Washington Eye Institute at Harborview</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Rath, COT</last_name>
      <phone>206-897-4331</phone>
      <email>raths@uw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 29, 2013</lastchanged_date>
  <firstreceived_date>December 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Shu-Hong Chang</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Size</keyword>
  <keyword>Pain</keyword>
  <keyword>Resolution</keyword>
  <keyword>Complications</keyword>
  <keyword>Swelling</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chalazion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
